Potential savings through single-dose intravenous Dalbavancin in long-term MRSA infection treatment - a health economic analysis using German DRG data.
Authors:
- 23 October 2019
- journal article
- Vol. 7, Doc03
Abstract
Complicated infections such as osteomyelitis, skin and soft tissue infections or endocarditis often require antibiotic therapies that can last up to several weeks. The prolonged hospital length of stay (LOS) leads to a dramatic increase in costs. Single-dose intravenous Dalbavancin is a novel antimicrobial agent for the treatment of acute bacterial skin, skin structure and soft tissue infections (ABSSSI) that allows an earlier discharge of patients, resulting in potential savings. Joint, bone and prostheses infections (JBPI) are also related with long LOS. The aim of this study is to determine the economic effects of single-dose intravenous Dalbavancin in suitable patients with Methicillin-resistant Staphylococcus aureus infections in Germany. For this purpose, an analysis with real-world patient treatment data was performed, which was subsequently validated in a large German hospital. In total, ABSSSI patients with MRSA infections could stay 6.45 days shorter and 2,865 € could be saved while JBPI patients could be discharged eventually 10.6 days earlier and 3,909 € could be saved. Single-dose intravenous Dalbavancin is thus an option for patients with ABSSSI and JBPI who are eligible for discharge.Keywords
This publication has 38 references indexed in Scilit:
- Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of ViennaClinical Infectious Diseases, 2018
- Management of spinal infection: a review of the literatureActa Neurochirurgica, 2018
- Appropriateness of antibiotic management of uncomplicated skin and soft tissue infections in hospitalized adult patientsBMC Infectious Diseases, 2016
- Early clinical assessment of response to treatment of skin and soft-tissue infections: how can it help clinicians? Perspectives from EuropeInternational Journal of Antimicrobial Agents, 2016
- New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancinTherapeutics and Clinical Risk Management, 2016
- Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative StudiesDrug Safety, 2015
- Burden of meticillin-resistant Staphylococcus aureus infections at a Swiss University hospital: excess length of stay and costsJournal of Hospital Infection, 2013
- The variance of length of stay and the optimal DRG outlier paymentsInternational Journal of Health Care Finance and Economics, 2008
- Effect of Linezolid versus Vancomycin on Length of Hospital Stay in Patients with Complicated Skin and Soft Tissue Infections Caused by Known or Suspected Methicillin-Resistant Staphylococci: Results from a Randomized Clinical TrialSurgical Infections, 2003
- Risk factors for hospital-acquired urinary tract infection in a large English teaching hospital: A case-control studyInfection, 1999